Home 
Today's Top Picks 
Top Performers 
Watchlist 
My Robo Portfolios 
ETF Zone 
Help & Tutorial 
Cancel anytime
- Chart
- Upturn Summary
- Highlights
- Valuation
Upturn AI SWOT - About
NAUT 
Nautilus Biotechnology Inc (NAUT)
- BUY Advisory
- SELL Advisory (Profit)
- SELL Advisory (Loss)
- Profit
- Loss
- Pass (Skip investing)
Stock price based on last close (see disclosures)
- ALL
- YEAR
- MONTH
- WEEK
Upturn Advisory Summary
08/28/2025: NAUT (1-star) is currently NOT-A-BUY. Pass it for now.
Upturn Star Rating
Not Recommended Performance
These Stocks/ETFs, based on Upturn Advisory, consistently fall short of market performance, signaling caution before investing.
Number of Analysts
4 Analysts rated it
Very few follow this stock; limited insights, higher-risk early investing.
1 Year Target Price $2.5
1 Year Target Price $2.5
| 2 | Strong Buy |
| 0 | Buy |
| 2 | Hold |
| 0 | Sell |
| 0 | Strong Sell |
Analysis of Past Performance
Type Stock | Historic Profit -43.86% | Avg. Invested days 23 | Today’s Advisory PASS |
Upturn Star Rating | Upturn Advisory Performance  1.0 | Stock Returns Performance  1.0 |
| Profits based on simulation | Last Close 08/28/2025 |
Key Highlights
Company Size Small-Cap Stock | Market Capitalization 86.77M USD | Price to earnings Ratio - | 1Y Target Price 2.5 |
Price to earnings Ratio - | 1Y Target Price 2.5 | ||
Volume (30-day avg) 4 | Beta 1.24 | 52 Weeks Range 0.66 - 3.09 | Updated Date 08/29/2025 |
52 Weeks Range 0.66 - 3.09 | Updated Date 08/29/2025 | ||
Dividends yield (FY) - | Basic EPS (TTM) -0.52 |
Earnings Date
Report Date 2025-07-31 | When - | Estimate -0.15 | Actual -0.12 |
Profitability
Profit Margin - | Operating Margin (TTM) - |
Management Effectiveness
Return on Assets (TTM) -19.3% | Return on Equity (TTM) -31.55% |
Valuation
Trailing PE - | Forward PE - | Enterprise Value -32918382 | Price to Sales(TTM) - |
Enterprise Value -32918382 | Price to Sales(TTM) - | ||
Enterprise Value to Revenue - | Enterprise Value to EBITDA -2 | Shares Outstanding 126305000 | Shares Floating 46279460 |
Shares Outstanding 126305000 | Shares Floating 46279460 | ||
Percent Insiders 33.34 | Percent Institutions 46.34 |
Upturn AI SWOT
Nautilus Biotechnology Inc
Company Overview
History and Background
Nautilus Biotechnology Inc. was founded in 2016. It went public via a SPAC merger in 2021. The company is focused on developing a single-molecule protein analysis platform.
Core Business Areas
- Protein Analysis Platform Development: Nautilus is developing a platform to enable single-molecule protein analysis to accelerate drug discovery and precision medicine.
Leadership and Structure
Suzi Glaser is the CEO. The company has a board of directors and a management team overseeing research and development, operations, and finance.
Top Products and Market Share
Key Offerings
- Single-Molecule Protein Analysis Platform (In Development): Nautilus is developing a platform for quantifying and understanding the proteome. The platform is not yet commercially available. Competitors include Quanterix (QTRX), SomaLogic (SLGC, now Standard BioTools, INST), and Olink (OLK).
Market Dynamics
Industry Overview
The proteomics market is growing rapidly, driven by increasing demand for protein-based biomarkers and personalized medicine. The life science tools market is highly competitive.
Positioning
Nautilus aims to differentiate itself with its single-molecule protein analysis approach, offering higher sensitivity and throughput. The company is currently pre-revenue and focused on product development.
Total Addressable Market (TAM)
The total addressable market for proteomics is estimated to be in the tens of billions of dollars. Nautilus is positioned to capture a portion of this market with its innovative platform. The global proteomics market size was valued at USD 27.18 billion in 2023 and is expected to grow to USD 63.99 billion by 2032.
Upturn SWOT Analysis
Strengths
- Novel single-molecule protein analysis technology
- Experienced management team
- Strong intellectual property portfolio
- Potential for high sensitivity and throughput
Weaknesses
- Pre-revenue stage
- Technology still in development
- High cash burn rate
- Dependence on key personnel
Opportunities
- Growing proteomics market
- Increasing demand for personalized medicine
- Potential for partnerships with pharmaceutical companies
- Expansion into new applications
Threats
- Competition from established players
- Technological challenges
- Regulatory hurdles
- Economic downturn
Competitors and Market Share
Key Competitors
- QTRX
- INST
- OLK
Competitive Landscape
Nautilus faces intense competition from established players in the proteomics market. Its success depends on demonstrating the superior performance and cost-effectiveness of its platform.
Growth Trajectory and Initiatives
Historical Growth: Nautilus has not yet generated revenue. Its growth is measured by its progress in developing its technology and securing partnerships.
Future Projections: Analyst estimates project revenue generation in the coming years, contingent on successful platform development and commercialization. Projections remain highly speculative due to the inherent risks of biotechnology startups.
Recent Initiatives: Recent initiatives include continued development of the protein analysis platform, presentations at scientific conferences, and strategic collaborations.
Summary
Nautilus Biotechnology is an early-stage company with a promising single-molecule protein analysis platform. The company faces significant risks, including technology development, competition, and funding. Its success depends on executing its development plan and demonstrating the value of its platform. It needs to generate revenue soon as well as avoid running out of cash.
Peer Comparison
Sources and Disclaimers
Data Sources:
- Company filings (SEC)
- Analyst reports
- Press releases
- Industry publications
Disclaimers:
This analysis is for informational purposes only and should not be considered investment advice. The data provided may not be comprehensive or accurate. Investors should conduct their own due diligence before making any investment decisions.
AI Summarization is directionally correct and might not be accurate.
Summarized information shown could be a few years old and not current.
Fundamental Rating based on AI could be based on old data.
AI-generated summaries may have inaccuracies (hallucinations). Please verify the information before taking action.
About Nautilus Biotechnology Inc
Exchange NASDAQ | Headquaters Seattle, WA, United States | ||
IPO Launch date 2021-06-10 | Co-Founder, CEO, President, Secretary & Director Mr. Sujal M. Patel | ||
Sector Healthcare | Industry Biotechnology | Full time employees 128 | Website https://www.nautilus.bio |
Full time employees 128 | Website https://www.nautilus.bio | ||
Nautilus Biotechnology, Inc., a development stage life sciences company, engages in creating a platform technology for quantifying and unlocking the complexity of the proteome. The company develops Nautilus Platform, a proteomics platform that includes end-to-end solution comprising instruments, consumables, and software analysis. It also offers proteome analysis system, a high-resolution optical imaging system with integrated fluidics and liquid handling sub-system to deposit protein libraries onto a flow cell and to process labeled multi-affinity reagent probe binding and imaging cycles rapidly to decode and quantify the proteins present in biological samples. In addition, the company offers reagent kits, which include sample preparation, flow cells, multi-affinity probe reagents, and instrument buffers system to perform multi-cycle analysis runs. Nautilus Biotechnology, Inc. was founded in 2016 and is headquartered in Seattle, Washington.
Note: This website is maintained by Upturn Corporation, which is an investment adviser registered with the U.S. Securities and Exchange Commission. Such registration does not imply a certain level of skill or training. Investing in securities has risks. Past performance is no guarantee of future returns. No assurance is provided as to any particular investment return, and you may lose money using our services. You are strongly advised to consult appropriate counsel before making any investments in companies you learn about through our services. You should obtain appropriate legal, tax, investment, accounting, and other advice that takes into account your investment portfolio and overall financial situation. You are solely responsible for conducting due diligence on a potential investment. We do not affect trades for you. You will select your own broker through which to transact. Investments are not FDIC insured, they are not guaranteed, and they may lose value. Please see the Privacy Policy, Terms of Use, and Disclosure for more information.